Vifor Pharma AG
VIFN.SW News Today: Stay Updated with the Latest Vifor Pharma AG News in Real Time
Find VIFN.SW news now at Meyka AI. Stay informed with the latest Vifor Pharma AG stocks updates, including price news, market analysis, and expert insights.
Leerink Maintains Outperform on BBIO, BridgeBio Pharma, Inc. March 12, 2026
Leerink maintains Outperform on BBIO on March 12, 2026 — analysis of implications and Meyka grade for BBIO analyst rating
Cantor Fitzgerald Keeps Overweight on Agios Pharmaceuticals, Inc. (AGIO) Mar 2026
Cantor Fitzgerald keeps Overweight on Agios (AGIO) March 12, 2026; we analyze the AGIO analyst rating and implications
CHF0.0015 trade in IGPH.SW IGEA Pharma (SIX) Mar 2026: Heavy volume, liquidity
Intraday update on IGPH.SW stock: CHF0.0015 trade on 2.03M volume, high volatility and Meyka AI forecast included
Trump Tariff Probe Into Switzerland Sparks Trade Risk — March 13
Donald Trump tariffs risk rises as a USTR probe targets Switzerland’s trade surplus. What it means for CHF, exporters, and portfolios in CH, plus key dates to watch.
Bank of America, Leerink Maintain Buy/Outperform on RARE Ultragenyx March 2026
BofA and Leerink maintain ratings on RARE. RARE analyst rating recap and investor implications
IDIA.SW Idorsia Ltd (SIX) down 9.00% to CHF3.54 on 12 Mar 2026: analyst focus
IDIA.SW stock fell 9.00% to CHF3.54 on SIX close 12 Mar 2026. Read Meyka AI analysis, grade and forecast
4597.T Solasia Pharma (JPX) pre-market: JPY 32.00 most-active on 13 Mar 2026, catalysts ahead
Pre-market update on 4597.T stock: **JPY 32.00**, volume 36.66M; valuation, pipeline and Meyka AI forecast
PreMkt 13 Mar 2026: 0503.HK Lansen Pharma HK +40.94% to HK$1.79: targets
Pre-market analysis of 0503.HK stock: HK$1.79, +40.94%, heavy volume. Meyka AI forecast HK$2.43 (35.90% upside)
Spain’s Almirall in Talks With Dozens of Firms to License China Assets, CEO Says
Spain’s pharmaceutical leader Almirall is making waves in the global health sector. The company has publicly confirmed that it is in active talks with dozens of firms in China. The goal? To license China‑based medicines and assets to partners who can help commercialize them beyond the local market. This comes as the company strengthens its…